BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32247788)

  • 21. Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.
    Inoue M; Toki H; Matsui J; Togashi Y; Dobashi A; Fukumura R; Gondo Y; Minowa O; Tanaka N; Mori S; Takeuchi K; Noda T
    Carcinogenesis; 2016 May; 37(5):452-60. PubMed ID: 26964870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment on: Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents: ROS1-fusion inflammatory myofibroblastic tumor: ROS1-fusion inflammatory myofibroblastic tumor.
    Wachter F; Janeway KA
    Pediatr Blood Cancer; 2023 Feb; 70(2):e29907. PubMed ID: 35920604
    [No Abstract]   [Full Text] [Related]  

  • 23. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
    J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EWSR1-SMAD3-rearranged Fibroblastic Tumor: An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic Neoplasms.
    Michal M; Berry RS; Rubin BP; Kilpatrick SE; Agaimy A; Kazakov DV; Steiner P; Ptakova N; Martinek P; Hadravsky L; Michalova K; Szep Z; Michal M
    Am J Surg Pathol; 2018 Oct; 42(10):1325-1333. PubMed ID: 29957732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder.
    Inamura K; Kobayashi M; Nagano H; Sugiura Y; Ogawa M; Masuda H; Yonese J; Ishikawa Y
    Hum Pathol; 2017 Nov; 69():96-100. PubMed ID: 28504207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
    Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALK-rearranged inflammatory myofibroblastic tumour of placental membranes.
    Squires L; Matsika A; Turner J; Fitness J; Lourie R
    Pathology; 2018 Dec; 50(7):777-779. PubMed ID: 30262185
    [No Abstract]   [Full Text] [Related]  

  • 30. TIMP3::ALK fusions characterize a distinctive myxoid fibroblastic tumor of the vocal cords: a report of 7 cases.
    Klubíčková N; Michal M; Agaimy A; Zidar N; Pavlovský M; Yorita K; Grossmann P; Hájková V; Ptáková N; Šteiner P; Michal M
    Virchows Arch; 2022 Nov; 481(5):721-729. PubMed ID: 35925390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of ROS1 Immunohistochemistry With
    Huang RSP; Smith D; Le CH; Liu WW; Ordinario E; Manohar C; Lee M; Rajamani J; Truong H; Li J; Choi C; Li J; Pati A; Bubendorf L; Buettner R; Kerr KM; Lopez-Rios F; Marchetti A; Marondel I; Nicholson AG; Öz AB; Pauwels P; Penault-Llorca F; Rossi G; Thunnissen E; Newell AH; Pate G; Menzl I
    Arch Pathol Lab Med; 2020 Jun; 144(6):735-741. PubMed ID: 31509456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma.
    Rossing M; Yde CW; Sehested A; Østrup O; Scheie D; Dangouloff-Ros V; Geoerger B; Vassal G; Nysom K
    Cancer Genet; 2017 Apr; 212-213():32-37. PubMed ID: 28449809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1.
    Haimes JD; Stewart CJR; Kudlow BA; Culver BP; Meng B; Koay E; Whitehouse A; Cope N; Lee JC; Ng T; McCluggage WG; Lee CH
    Am J Surg Pathol; 2017 Jun; 41(6):773-780. PubMed ID: 28490045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor.
    Mai S; Xiong G; Diao D; Wang W; Zhou Y; Cai R
    Lung Cancer; 2019 Feb; 128():101-104. PubMed ID: 30642440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ROS1 copy number alterations are frequent in non-small cell lung cancer.
    Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
    Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
    Davies KD; Le AT; Sheren J; Nijmeh H; Gowan K; Jones KL; Varella-Garcia M; Aisner DL; Doebele RC
    J Thorac Oncol; 2018 Oct; 13(10):1474-1482. PubMed ID: 29935306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytologic findings in ectopia of the decidua (deciduosis) of the portio vaginalis uteri].
    Wunderlich M
    Zentralbl Gynakol; 1986; 108(15):925-9. PubMed ID: 3765948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.